cemiplimab
iratumumab
volociximab
atezolizumab
olaratumab
pidilizumab
fontolizumab
gevokizumab
ravulizumab
etaracizumab
tislelizumab
zalutumumab
amlitelimab
inotuzumab ozogamicin
abagovomab
brolucizumab
sibrotuzumab
-lim-
bivatuzumab
ozogamicin
olendalizumab
lexatumumab
intrabody
ipilimumab
antimonoclonal
-toxa-
-zumab
dalotuzumab
agonistic monoclonal antibody
rapid antigen test
tabalumab
tigatuzumab
immunochemiluminometric
microlymphocytotoxicity
brodalumab
Forssman antibody
heterophile antibody
heterophil antibody
durvalumab
immunofluorescence
immunostrip
talacotuzumab
immunolabeling
lenzilumab
antinucleosome
bectumomab
robatumumab
siltuximab
-o-
ocrelizumab